Find your next paid study

The Methodist Hospital Research InstituteNCT06566443

~$150 – $3,000

Actual pay is set by the research site.

CancerTumor, SolidMalignant Neoplasm+4 more

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokineti…

OncoResponse, Inc.NCT06090266

Actual pay is set by the research site.

Advanced Breast CarcinomaAdvanced Endometrial CarcinomaAdvanced Fallopian Tube Carcinoma+71 more

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel an…

Phase 2

A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-sei…

SeizuresPrimary Motor CortexBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+2 more

Ayal A. Aizer, MDNCT07130786

~$75 – $3,000

Actual pay is set by the research site.

Non-small Cell Lung Cancer

Combination Of Izalontamab Brengitecan And Adagrasib In Advanced KRAS G12Ci-Refractory Non-Small Cell Lung Cancer - The IZA-A Trial

This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NS…

M.D. Anderson Cancer CenterNCT07382726

~$150 – $3,000

Actual pay is set by the research site.

Phase 2

Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of le…

Bladder Squamous Cell CarcinomaLocally Advanced Bladder CarcinomaMalignant Renal Pelvis Neoplasm+8 more

Emory UniversityNCT05756569

~$75 – $2,000

Actual pay is set by the research site.

Phase 3

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic …

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Merck Sharp & Dohme LLCNCT06136559

~$50 – $2,100

Actual pay is set by the research site.

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (…

NYU Langone HealthNCT05815173

~$150 – $4,500

Actual pay is set by the research site.

Carcinoma, Non-Small-Cell Lung CancerBone Metastases From Solid Tumors

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally ad…

Kiromic BioPharma Inc.NCT06069570

Actual pay is set by the research site.

Triple Negative Breast CancerHormone-Resistant Breast CancerNon Small Cell Lung Cancer+1 more

FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recomb…

A&G Pharmaceutical Inc.NCT05627960

Actual pay is set by the research site.

Phase 2

A Multicenter Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax (BOSon) or Tacabrutideg (BGB-16673), Obinutuzumab, and Sonrotoclax (DOSon) in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated ch…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)

Massachusetts General HospitalNCT06849713

~$75 – $2,000

Actual pay is set by the research site.

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung …